⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30265312 | 0.82 | KDM4C (0.41) | — | |
| SCHEMBL30457937 | 0.73 | TSHR (0.47) | — | |
| SCHEMBL12597545 | 0.73 | — | — | |
| SCHEMBL141814 | 0.71 | — | — | |
| SCHEMBL31096976 | 0.71 | — | — | |
| SCHEMBL7821222 | 0.71 | — | — | |
| SCHEMBL5415498 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL2240887 | 0.69 | — | — | |
| SCHEMBL9086982 | 0.69 | TSHR (0.42) | — | |
| SCHEMBL11675279 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | claimed |
| WO-2025052429-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TIRZEPATIDE | NEULAND LABORATORIES LIMITED (IN) | 2025-03-13 | — | — | WO | claimed |
| US-20250382344-A1 | Soluble GLP1/GIP/NPY2 Receptor Triple Agonists | BOEHRINGER INGELHEIM INT GMH (DE) | 2025-12-18 | — | — | US | disclosed |
| WO-2025052429-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF TIRZEPATIDE | NEULAND LABORATORIES LIMITED (IN) | 2025-03-13 | — | — | WO | disclosed |
| US-20240360194-A1 | New Peptides as Potent and Selective GIP Receptor Agonists | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024127333-A1 | CYTOTOXIC COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2024-06-20 | — | — | WO | disclosed |
| WO-2023211934-A1 | LIPIDS, FORMULATIONS, AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023137326-A2 | DE NOVO DESIGNED MEMBRANE-TRAVERSING AND ORALLY BIOAVAILABLE MACROCYCLES | UNIVERSITY OF WASHINGTON (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023081762-A2 | SERINE RECOMBINASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022232567-A2 | CYCLIC PEPTIDE INHIBITORS OF USP22 | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-11-03 | — | — | WO | disclosed |
| WO-2018161035-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH ONE OR MORE THERAPEUTIC AGENTS | MACREGEN, INC. (US) | 2018-09-07 | — | — | WO | disclosed |
| EP-2480552-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2016-11-09 | — | — | EP | disclosed |
| WO-2016176555-A1 | PROSTACYCLIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | INSMED INCORPORATED (US) | 2016-11-03 | — | — | WO | disclosed |
| US-RE38828-E1 | Parevins and tachytegrins | INTRABIOTICS PHARMACEUTICALS, INC. (US) | 2005-10-11 | — | — | US | disclosed |
| US-20020147301-A1 | Parevins and tachytegrins | INTRABIOTICS PHARMACEUTICALS, INC. | 2002-10-10 | — | — | US | disclosed |
| US-6307016-B1 | BROAD-SPECTRUM ANTIMICROBIAL PEPTIDES EFFECTIVE AGAINST A WIDE VARIETY OF MICROBES, INCLUDING BACTERIA; ANTIBIOTIC PEPTIDES | INTRABIOTICS PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |